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SHORT COMMUNICATION
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ABSTRACT
Oregonin is an open-chain diarylheptanoid isolated from Alnus incana bark that possesses remarkable anti-
oxidant and anti-inflammatory properties, inhibits adipogenesis, and can be used in the prevention of
obesity and related metabolic disorders. Here, we aimed to investigate the effects of oregonin on the
epigenetic regulation in cells as well as its ability to modulate DNA methylating enzymes expression and
mitochondrial DNA (mtDNA) copies. Our results show that oregonin altered the expression of DNA methyl-
transferases and mtDNA copy numbers in dependency on concentration and specificity of cells genotype.
A close correlation between mtDNA copy numbers and mRNA expression of the mtDnmt1 and Dnmt3b
was established. Moreover, molecular modeling suggested that oregonin fits the catalytic site of DNMT1
and partially overlaps with binding of the cofactor. These findings further extend the knowledge on orego-
nin, and elucidate for the first time its potential to affect the key players of the DNA methylation process,
namely DNMTs transcripts and mtDNA.
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1. Introduction
Oregonin 1,7-bis-(3,4-dihydroxyphenyl)-3-hydroxyheptane-5-O-b-D-
xylopyranoside (Figure 1) is an open-chain diarylheptanoid glyco-
side that contains 3-carbonyl and 5-xylosyloxy groups, and is the
predominant compound in the hydrophilic extracts from the Alnus
incana bark1,2. This natural compound possesses noticeable anti-
oxidative and anti-inflammatory properties, inhibits the adipogene-
sis and can be used in the prevention of obesity and related meta-
bolic disorders3–8.
The effects of oregonin, isolated from the bark of grey alders
growing in Latvia, have been tested in vitro on blood samples
from volunteers with clinically confirmed metabolic syndromes.
The total and low-density cholesterol as well as the level of triacyl-
glycerols is reduced by 30%, 20% and 30%, respectively, after
incubation with alder bark ethyl acetate extract containing 60% of
oregonin or with purified oregonin for 30min1. The effect has also
been confirmed in white rats in vivo1,9. Pure oregonin from
A. incana increases glutathione peroxidase and superoxide dismu-
tase activity, and decreases the activity of lipase, catalase and
malondialdehyde level (indicator of lipid peroxidation) in blood
in vivo1,9. Also, it reduces lipid accumulation, inflammation and
ROS production in primary human macrophages, indicating its
anti-inflammatory activity10.
Oregonin shares chemical features and substructure with the
well-known dietary antioxidant curcumin, which is widely used as
a bioactive constituent of food supplements. Some studies9,11
have shown that oregonin expressed higher antioxidant activity
and some others biological activities, particularly antibacterial and
antifungal, than curcumin. While curcumin potential role in the
epigenetic changes is described12,13, to the best of our knowledge
no reports on the effects of oregonin from A. incana on the epi-
genetic regulation in cells are available to date.
Epigenetic changes cover altered DNA methylation, histone
modification, non-coding RNAs and chromatin remodeling14,15.
DNA methylation is regulated by enzymes belonging to the DNA
methyltransferases (DNMTs) family, which transfer methyl groups
from S-adenosyl-L-methionine (SAM) to the 5-position of the cyto-
sine pyrimidine ring16. Hyper-methylation of DNA often occurs in
gene-specific promoters mostly in gene-rich genomic regions
(CpG-islands) and can lead to the inhibition of gene expression
(gene silencing), while hypo-methylation is observed in repetitive
elements all over the genome14,17. Increasing evidences are accu-
mulating on the importance of mitochondria in the epigenetic
regulation of cells. It is known that mitochondria are able to influ-
ence cytosine methylation levels in the nucleus by modulating the
flux of one-carbon units for the generation of SAM, the methyl
donor in DNA methylation18. As reported by Smiraglia et al.19,
many genes undergo changes in their methylation status in
response to the depletion and repletion of mtDNA. Mitochondrial
dysfunction could cause alterations in redox (reduced oxygen)
reactions and SAM-CH3 production in the cell, leading to per-
turbed methylation of nuclear encoded genomic DNA18.
A strong correlation between epigenetic alterations, including
mitochondrial factors, and human diseases, especially cancer, has
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been observed19–21. Experimental evidences have pointed that
polyphenols have great potential as epigenetic modulators, influ-
encing various epigenetic factors such as histone acetyltransfer-
ases22, DNTMs and miRNAs23–26. These findings13,27–29 have
increased the enthusiasm in developing therapeutic strategies for
many diseases through targeting the various epigenetic factors by
polyphenols. Accordingly, the identification of new natural and
nontoxic polyphenols, able to affect reversibly the epigenetic
deregulation, is nowadays a well-established and promising scien-
tific topic.
Using a combination of biological and computational modeling
tools, the present study aims to investigate whether the isolated
and purified polyphenol oregonin from A. incana bark can affect
the key players of the DNA methylation process, namely DNA
methylating enzymes and mitochondrial DNA (mtDNA) in mouse
embryonic fibroblasts (MEFs).
2. Materials and methods
2.1. Oregonin extraction
Bark of A. incana (Grey alder) was collected in November 2015
from trees growing in Latvia. Diarylheptanoids were obtained
using accelerated solvent extraction with ethyl acetate after
removal of lipophilic extractives (EtOAc). The bark was extracted
with pressurised ethyl acetate in an ASE 350 apparatus (Dionex,
Sunnyvale, CA) by applying 3 5min static cycles at 90 C and
10.3MPa. The solvent was evaporated in vacuo, the extract was
freeze-dried and stored at 20 C.
Analysis of A. incana extract was performed on ACQUITY UPLC
H-Class (Waters, Singapore) with ACQUITY UPLC PDA Detector
coupled with SYNAPT G2-Si High Definition Mass Spectrometry
(Waters, Milford, Massachusetts, MA, USA). Column was Waters
ACQUITY UPLC BEH C18, 2.1 50mm, 1.7mm, flow 0.5ml/min,
Mobile phase A: waters þ0.1% formic acid, B: acetonitrile, gradient
from 10% A to 100% B, injection 2mL. Mass range (50–1200Da),
ESI negative mode, cone voltage 40 V, scan time 0.1 s, desolvation
gas nitrogen (600 L/h), source temperature at 120 C.
Oregonin was purified from alder bark EtOAc extract by SP1TM
Purification System using Biotage column KP-C18-HS (12 150mm,
35–70lm) with solvent systems: solvent A¼ ethanol/water/acetic
acid (200: 790: 10, v/v) and solvent B¼ ethanol. The gradient was
from 0 to 25% solvent B. Identification and purity state of oregonin
was determined using UPLC-PDA-MS/MS, NMR methods. The proof
quality is assessed by comparison to the oregonin reference stand-
ard [95% (LC/MS-ELSD)] purchased from Sigma-Aldrich (Saint
Louis, MA, USA). For the investigation of antioxidant activity, the
methods of the deactivation of 2,2-diphenyl-1-picrylhydrazyl
(DPPH) and 2,20-azinobis-(3-ethylbenzothiazoline-6-sulfonic acid
(ABTSþ) radicals were applied.
2.2. Animals
The animals used for obtaining the mouse embryonic cells were
reared and handled in vivarium of the IBIR-BAS in accordance with
Bulgarian Veterinary Law (25/01/2011) regarding the life conditions
and welfare of experimental animals, which is adapted to the
European Union regulation 86/609 and Directive 2010/63/EU. The
experimental protocols were approved by the National Ethics com-
mission for animals (“Permission for using animals in the
experiments”, N84/04.10.2013, expiry date 04.10.2018). The individ-
ual responsible for the animal welfare, which works directly with
the animals used in the study, is licensed by the Bulgarian veterin-
ary services for animal experimentation. Animals were anesthetised
before sacrificing them. All efforts were made to minimise suffering.
2.3. Cell cultures
MEFs were prepared from 13- to 14-day-old embryos of ICR mice.
After dissection of the red organs, the tissues were minced and
digested with 0.25% trypsin/EDTA (Sigma-Aldrich, Saint Louis, MA,
USA). Dissociated cells were grown in monolayers at 37 C in a
humidified atmosphere of 5% CO2 and 95% air using Dulbecco’s
Modified Eagle Medium (DMEM) with 1.0 g/L glucose (PAN-
Biotech, Aidenbach, Germany) as the culture medium. DMEM was
supplemented with 10% fetal bovine serum (Sigma-Aldrich , Saint
Louis, MA, USA) and penicillin, streptomycin, amphotericin B mix
(PAN-Biotech, Aidenbach, Germany). Mouse embryo fibroblast cell
line, NIH/3T3, was obtained from the American-Type Culture
Collection (Manassas, VA, USA). Cells were cultured under the con-
ditions used for MEFs.
2.4. Cell viability assay
Cell viability was estimated by 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) assay (Sigma-Aldrich, Saint
Louis, MA, USA), which is based on the cleavage of a tetrazolium
salt by mitochondrial dehydrogenases in viable cells. NIH/3T3 cells
and MEFs were seeded in sterile flat bottom 96-well plates at a
density of approximately 2 104 cells/well and allowed to attach
overnight at 37 C. The cells were then exposed to 50 and
100 lM oregonin dissolved in culture medium for 24 and 48 h.
Untreated cells and blank wells (without cells) received 100 ll of
the culture medium. After incubation with oregonin, the culture
Figure 1. (a) Base peak ion chromatogram of purified (90% oregonin) alder bark
extracts obtained by negative ion UPLC-ESI-MS. Oregonin (2), (3R,5S)-1,7-bis-(3,4-
dihydroxyphenyl)-3-hydroxyheptane-5-O-b-D-xylopyranoside (1) and hirsutanolol
(3). (b) Chemical structure of compounds 1–3.
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medium was removed and 100 ll of MTT at the concentration of
500 lg/ml in culture medium was added to the wells. Cells were
incubated in a humidified CO2 incubator for another 3 h. Then,
the MTT solution was removed and 100 ll of dimethyl sulfoxide
(DMSO, Merck, Darmstadt, Germany) was added to dissolve for-
mazan crystals. Absorbance at 544 nm was monitored with a
plate reader (FLUOstar Optima, BMG Labtech, Offenburg,
Germany) to obtain the number of viable cells relative to the
control population. Data are expressed as mean values ± SD and
obtained from three different experiments against each cell type.
2.5. Quantitative real-time PCR (qRT-PCR) assay
Fibroblasts were plated in sterile six-well plates at a density
2 105 cells/well and were left to adhere overnight. Cells were
treated with 50 and 100 lM oregonin in culture medium for 24 h.
The samples were collected and subjected by TriReagent (Sigma-
Aldrich, Saint Louis, MA, USA) in accordance with producers’
instruction for total RNA and genomic DNA extractions.
2.5.1. Dnmts mRNA expression
The extracted RNA was used for the synthesis of the first cDNA
strands using cDNA synthesis kit (Thermo Fisher Scientific,
Waltham, CA, USA). qRT-PCR was performed on Dnmt1; mtDnmt1,
Dnmt3a and Dnmt3b genes using SYBR Green PCR Master Mix
(Life Technologies, Waltham, CA, USA). The primers are presented
in Table 1. b-actin was selected as a housekeeping gene.
All primers were obtained from Sigma-Aldrich, Saint Louis, MA,
USA. PCR analysis was performed using a two-step cycling protocol,
which was optimised under the following conditions: cycles con-
sisted of a 10-min initial denaturation phase at 95 C, a 15-s denatur-
ation phase at 95 C and a 20-s annealing phase based on the Tm of
the primers (55–60 C) with the last two steps repeated for a total of
40 cycles. A melting curve was made after cycling by changing the
temperature from 60 to 90 C and read and recorded every 1 C. The
process was implemented on MastercyclerVR ep realplex (Eppendorf,
Hamburg, Germany). The presence of all Dnmts forms in the PCR
product was confirmed by gel electrophoresis (Figure 2).
2.5.2. mtDNA copy number evaluation
The purity and concentration of extracted DNA was measured
using Nano Drop 1000 (Thermo Fisher Scientific, Waltham, MA
USA). A ratiometric assay30 of the levels of a single mitochondrial
gene cytochrome B (Cytb) against a single copy nuclear gene
(b-actin) was used to estimate the average copy value of mtDNA/
per cell. This technique allows the calculation of average mtDNA
copy number/cell without the necessity to estimate cell number.
Primers and probes were obtained from Sigma-Aldrich, Saint
Louis, MA, USA on the base of sequences mouse genes used by
Aiken et al.31 (Table 2). Probes were labelled fluorescently with
carboxyfluorescein (FAM) (50 end) and carboxytetramethylrhod-
amine (TAMRA) (30 end). TaqMan Master Mix (Applied Biosystems,
Foster City, CA, USA) was used for the reaction. The PCR condi-
tions were following: initial steps at 50 C for 2min and 95 C for
15min, followed by 40 cycles of 15 s at 95 C and 1min at 65 C.
Standard curves were created separately for every sample from a
dilution series to ensure the efficiency of reaction. The cycle
threshold (CT) value for b-actin was subtracted from that for Cytb
to give the value DCt. Average mtDNA copy number30 per nuclear
genome (two actin gene copies) is calculated as 2 2(DCt).
2.6. Statistical development of the results
All analyses were performed with Statistica software (StatSoft10,
Tulsa, OK, USA). Student’s t-test was used for comparison between
groups. Pearson’s correlation test was applied to measure the rela-
tionship between investigated parameters. Values of p< .05 were
considered significant. Data are presented as a mean± SD, and
triplicate repetition of the experiments was done.
PCR data were analysed by DataAssist Sft. (Ver. 3.01, Applied
Biosystems, Foster City, CA, USA) using DCt method32. The results
were expressed as the mean of target to control gene expression
ratio [fold changes (FC)]. For the evaluation of the oregonin effect,
DDCt method32 was applied for the comparison between control
and experimental groups. Genes with fold change cutoff of 2
and p values 0.05 compared with the control were considered to
be upregulated, while with FC 0.5 and p 0.05 were considered
to be downregulated. FC values between 0.5 and 2 indicated no
significant change in gene expression.
2.7. Molecular modelling
The possible binding mode of oregonin to DNMT1 was predicted
by molecular docking. The crystallographic structure of human
DNMT1 in complex with S-adenosyl-L-homocysteine (SAH) coded
by PDB 4WXX33 was retrieved from the Protein Data Bank (www.
rcsb.org/pdb) and used as rigid receptor. As in our previous
work34, molecular docking simulations were performed by FRED
program from OpenEye (version 3.0.1)35,36. The receptor was
Table 1. Primer sequences for mouse Dnmt genes and b-actin.
Genes Sequence (50!30) Size (bp) Tmb (C)
Dnmt1 F: GGGTCTCGTTCAGAGCTG 201 60
R: GCAGGAATTCATGCAGTAAG
mtDnmt1 F: TCTCTTGCCCTGTGTGGTACATG 164 60
R: TCTTTCCAAGTCTTTGAGCCGCC
Dnmt3a F: CCGCCTCTTCTTTGAGTTCTAC 125 55
R: AGATGTCCCTCTTGTCACTAACG
Dnmt3b F: ATGGAGATCAGGAGGGTATGGA 177 56
R: GTCGCTTGGAGGTGGCTTTC
b-actin F: GACCCAGATCATGTTTGAGACC 122 60
R: ATCAGAATGCCTGTGGTACGAC
Figure 2. Agarose gel electrophoresis of PCR product (Dnmts).
Table 2. Primers and probes for mtDNA copy analysis.
Genes Sequence (50!30)
Cytochrome B F: TTTTATCTGCATCTGAGTTTAATCCTGT
R: CCACCTCATCTTACCATTTATTATCGC
Cytochrome B probe FAM-AGCAATCGTTCACCTCCTCTTCCTCCAC-TAMRA
b-actin F: GGAAAAGAGCCTCAGGGCAT
R: CTGCCTGACGGCCAGG
b-actin probe FAM-CATCACTATTGGCAACGAGCGGTTCC-TAMRA
FAM: carboxyfluorescein; TAMRA: carboxytetramethylrhodamine.
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prepared with the make_receptor utility by centring the binding
site on the SAH ligand. The 3D structures of curcumin (reference
control) and oregonin were downloaded from PubChem37.
Ligands conformational analysis was carried out with OMEGA from
OpenEye (version 2.5.1.4)38,39 by storing up to 600 conformers
including the initial structure, sampling hydrogen positions for
–OH groups and using all other parameters at their default values.
3. Results
3.1. Oregonin
The lyophilic dried oregonin isolated from A. incana bark
EtOAc extract and used in all investigations contained 90± 0.8% of
oregonin (2) (C24H30O10, UV kmax 281 nm. ES-: m/z 477 [M-H]
,
M¼ 478.50 g/mol, 5 ± 0.1% of 1,7-bis-(3,4-dihydroxyphenyl)-3-
hydroxyheptane-5-O-b-D-xylopyranoside (1) (C24H32O10, UV kmax
282 nm. ES-: m/z 479 [M-H], M¼ 480.52 g/mol) and 4± 0.1% of
hirsutanolol (3) (C19H22O6, UV kmax 281 nm. ES-: m/z 345 [M-H]
,
M¼ 346.38 g/mol) (Figure 1).
The oregonin powder from A. incana showed high antioxidant
activity. The following IC50 concentrations (required to scavenge
50% of free radicals) were reported: in ABTSþ 3.14 ± 0.13mgmL1
and in DPPH 4.52 ± 0.16mgmL1 respectively compared to
synthetic antioxidant trolox (a water-soluble vitamin E analogue),
whose IC50 values in tests were 4.01 ± 0.12 (ABTS) mgmL1 and
4.72 ± 0.12 (DPPH) mgmL1.
3.2. Effect of oregonin on viability of cells in vitro
Untreated control MEFs exhibited normal fibroblast morphology at
48 h (Figure 3(a)). Upon incubation of MEFs with increasing con-
centrations of oregonin for 48 h, apoptotic morphological changes
in a few cells were observed. The shapes of the oregonin treated
NIH/3T3 were similar to those of the untreated cells. The potency
of oregonin to reduce cell viability of MEFs and NIH/3T3 is shown
in Figure 3(b). After 24 h treatment with 100mM oregonin, MEFs
viability was decreased by 18% (t-test p< .05). After 48 h of orego-
nin treatment in concentrations 50 and 100 mM, MEFs viability
declined significantly by 16.7% and 15.8%, respectively. Both con-
centration of oregonin showed no growth inhibiting effect in NIH/
3T3 cells after treatment of 24 and 48 h.
3.3. Effect of oregonin on the Dnmts expression and mtDNA
copy number
A significant increase of mtDNA copy numbers in oregonin treated
MEF and NIH/3T3 cells was found (Figure 4). The highest effect
Figure 3. Effect of oregonin on MEFs and NIH/3T3 cells. (a) Cells grown 48 h in absence or presence of oregonin did not show significant changes in morphology. (b)
Cell viability in MEFs and NIH/3T3 cells treated with 50 and 100mM oregonin.
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was observed in MEFs incubated with 100 lM oregonin (increase
with 3.37 fold). The number of the mtDNA copy in NIH/3T3 cell at
50lM and 100 lM increased only with 0.17 and 0.39 fold,
respectively.
Purified oregonin in dose 50 lM down-regulated mRNA tran-
scripts of Dnmt1 in both NIH/3T3 and MEFs and had no effect on
the Dnmt3a at 24 h of incubation (Figure 5(a,b)).
The mtDnmt1 transcripts in NIH/3T3 cells were unchanged
(FC¼ 0.8) while in MEFs their level increased (FC¼ 2.31, p< .05).
The Dnmt3b transcripts were unaffected in MEFs, but downregu-
lated in NIH/3T3 cells. Oregonin in dose 100 lM up-regulated
mtDnmt1 and Dnmt3b in both cell types (FC> 2.0, p< .05). MEFs
treated with this concentration of oregonin showed increased
expression of Dnmt3a, but had no effect on Dnmt1 mRNA
transcripts. At the same experimental conditions (100lM) in
NIH3T3 cells, a drastic increase of Dnmt1 (FC¼ 9.51, p< .05) was
observed, whereas no alterations were found on Dnmt3a mRNA
transcripts.
The correlative analysis showed the different relationships
between expressed Dnmts in MEF and NIH/3T3 cells. A high posi-
tive correlation was determined between mtDnmt1 and Dnmt3b as
well as between Dnmt3b and Dnmt3a in MEFs (Table 3). In NIH/
3T3 cells, we observed a similar relationship between mtDnmt1
and Dnmt3b. Additionally, the changes in the expression of total
Dnmt1 closely correlated with changes in the expression of
mtDnmt1 and Dnmt3b.
The interesting finding was the definition of the close relation-
ship between mtDNA copy number and expression of mtDnmt1
and Dnmt3b in MEFs (Table 4).
3.4. Molecular docking of oregonin to DNMT1
The work of Liu et al.12 has clearly substantiated the possible
covalent binding of curcumin to DNMT1 in correspondence of
Cys1226 as a mechanism of hypomethylation. Based on the chem-
ical similarity between curcumin and oregonin, and sustained by
biological activity data described above, here we aimed to eluci-
date the possible binding of oregonin to DNMT1 and the respect-
ive pharmacophores. To this aim, we performed molecular
docking simulations of curcumin (used as reference control) and
oregonin towards the crystallographic structure of human DNMT1
in complex with SAH33. Results of our study were nicely in agree-
ment with the binding mode of curcumin predicted by Liu et al.12
Figure 4. mtDNA copy numbers in MEF and NIH/3T3 cells treated with oregonin.
The data are presented as a mean± SD of three independent experiments.	p< .05; 		p< .01; 			p< .001 compared to control.
Figure 5. DNA methyltransferases mRNA expression in MEF (a) and NIH3T3 (b)
cells incubated with oregonin in doses 50 and 100lM for 24 h. The data are pre-
sented as a mean± SD of three independent experiments. Fold change cut-off of
2 and p values 0.05 compared with the control were considered to be upre-
gulated, while with FC 0.5 and p .05 were considered to be downregu-
lated. 	p< .05.
Table 3. Correlative relationship between expression of Dnmts in NIH/3T3 and
MEF cells.
FC mtDnmt1 Dnmt3b Dnmt1 Dnmt3a
MEFs R
mtDnmt1 – 0.995 0.785 0.993
p = 0.033 p = 0.42 p = 0.074
Dnmt3b 0.995 – 0.816 0.997
p = 0.033 p = 0.39 p = 0.041
Dnmt1 0.785 0.816 – 0.852
p = 0.42 p = 0.39 p = 0.35
Dnmt3a 0.993 0.997 0.816 –
p = 0.074 p = 0.041 p = 0.39
NIH/3T3 R
mtDnmt1 – 0.998 0.999 0.803
p = 0.02 p = 0.003 p = 0.406
Dnmt3b 0.998 – 0.998 0.821
p = 0.02 p = 0.017 p = 0.387
Dnmt1 0.999 0.998 – 0.806
p = 0.003 p = 0.017 p = 0.403
Dnmt3a 0.803 0.821 0.806 –
p = 0.406 p = 0.387 p = 0.403
R: Pearson’s correlation coefficient; FC: folder change; significance of
results p< .05.
Table 4. Correlation between mtDNA copy number and Dnmts expression in
mouse fibroblasts.
FC mtDnmt1 Dnmt3b Dnmt1 Dnmt3a
MEFs R
Cn-mtDNA 0.999 0.999 0.797 0.995
p¼ 0.012 p¼ 0.021 p¼ 0.413 p¼ 0.062
NIH/3T3 0.836 0.818 0.833 0.344
Cn-mtDNA p¼ 0.370 p¼ 0.389 p¼ 0.373 p¼ 0.776
R: Pearson’s correlation coefficient; Cn-mtDNA: copy number of mitochondrial
DNA; FC: folder change; significance of results p< .05.
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towards the DNMT1 homology model (data not shown), and sug-
gested for the first time the geometric fitting of oregonin within
the catalytic site of DNTM1 (Figure 6). In particular, oregonin binds
in proximity of the cofactor binding cleft of DNMT1 and partially
overlaps with the crystallographic binding conformation of SAH.
This interaction is reinforced by a number of H-bonds established
with residues Ser1146, Glu1168, Trp1170, Glu1266, Arg1310, and
Arg1312 (Figure 6). The sugar moiety occupies a sub-pocket of
DNMT1 and nicely overlaps with the homocysteine moiety of SAH,
thus further suggesting that DNMT1 inhibition by oregonin may
be due to the competition with the cofactor SAH, as already
observed34 for different type of epigenetics regulators. Similar to
curcumin, oregonin does not interact directly with the key residue
Cys1226, even though it is located in close proximity of oregonin
in docking results (minimum distance between the thiol group of
Cys1226 and oregonin is 3.7 Å). Moreover, oregonin establishes
H-bonds with Glu1168 and Arg1312, which have been already
highlighted as crucial anchor points for the binding of curcumin
derivatives in the work of Liu et al.12 Different from curcumin, ore-
gonin does not possess chemically reactive groups that might
interact covalently with Cys1226, thus the binding of oregonin to
DNMT1 is expected to be non-covalent and reversible. Finally, the
Chemgauss4 affinity score calculated by the docking program is
slightly better for curcumin than oregonin (11.25 vs. 10.99,
respectively; the lower the better).
4. Discussion
4.1. Cell viability
The results of the cell viability test are in agreement with data
obtained for the oregonin extracted from others genus of Alnus.
The period of incubation 72 h and the concentrations of oregonin
from Alnus japonica between 0 and 50mM had no negative effects
on the viability and morphology of endothelial cells40. Under the in
vivo studies have shown the low toxicity of oregonin from A. gluti-
nosa41 in the experiments with brine shrimps and from A. japonica7
– with specific pathogen-free ICR mice. It was reported42 that diary-
lheptanoids from Alnus nepalensis show high biological activities
without any side effect at high oral dose. Compared to other poly-
phenol with similar structure, particularly curcumin, oregonin is less
toxic. In fact, curcumin in dose 50 lM in in vitro experiments43
reduced the cell viability more than 50%, whereas in our study the
lowest percent of viable cells treated with oregonin in dose 50 lM
was more than 80%. The results from our study clearly showed that
oregonin from bark of A. incana in doses of 50 and 100 lM had no
effect on the viability of NIH3T3 cells in the frame of 48 h and
expressed middle toxically effect on MEFs (up to 18%).
4.2. mtDNA copy number and Dnmts
Changes in mtDNA copy number have been reported in a broad
range of human diseases44, such as diabetes and its complications,
obesity, cancer, HIV complications and ageing. Our interest in the
investigation of this parameter was triggered by the evidence of
important role of mitochondria in the DNA methylation process
and remarkable antioxidant properties of oregonin. Results
described in this work clearly show the ability of oregonin to
increase the mtDNA content in the investigated cells although this
effect is quantitatively dependent on the cell type, as NIH/3T3 cells
showed more genomic stability than MEFs. The drastic increase of
mtDNA content in MEFs treated with 100 lM was accompanied by
a decrease of cell viability at 24 h. Most likely, there is an adaptive
response to increase oxidative stress by an enhancement of mito-
chondrial biogenesis due to toxic dose of oregonin44. On the other
hand, these changes also correspond to the increase of Dnmts
expression in MEFs. Our study highlighted for the first time the
close relationship between changes in mtDNA content and expres-
sion of Dnmts mRNAs, which could be explained by considering
that DNMTs enzymatic function is depended on the methyl donor
SAM, whose proper production is guaranteed also by mitochon-
dria18. The dependence of the DNA methylation process on the
mitochondria content is confirmed by Smiraglia et al.19, who ana-
lyse the methylation status of several genes in response to the
depletion and repletion of mtDNA. However, the mechanism pro-
voked by oregonin to increase the mtDNA replication is still
unclear. The replication of the mitochondrial genome is regulated
Figure 6. Binding mode of oregonin to DNMT1 crystallographic structure as predicted by molecular docking simulations. Oregonin is shown as cyan sticks; the crystal-
lographic structure of DNMT1 (PDB: 4 WXX)31 is shown as green cartoon; residues within 5 Å from Oregonin are showed as green lines; Cys1226 is shown as green
sticks. H-bonds are highlighted as magenta dashed lines; DNMT1 residues H-bonded to oregonin are labelled. Residues that are contacted by curcumin and its ana-
logues in Liu et al.’s study12 are labelled and underlined.
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via the actions of a combination of gene expression coding in
mtDNA and nuclear DNA such as D-loop region of mtDNA, TFAM,
RNA polymerase (POLRMT), DNA polymerase POLG, transcription
factors 1 and 2 (TFB1Mand TFB2M), nuclear respiratory factors 1
and 2 (NRF-1, NRF-2) and peroxisome proliferator-activated recep-
tor gamma coactivator 1-alpha (PGC1-a)45–48. Oregonin could
affect these genes via genetic or epigenetic pathways due to its
ability to change the expression of Dnmts. Additionally, the anti-
oxidative properties of oregonin result in an alteration of the
mRNA expression of several antioxidant-related genes and oxida-
tive stress responsive genes10, which could explain the increase in
mtDNA copy number through the communication between
nuclear and mitochondrial genes.
Changes in the mtDNA content and expression of Dnmts
mRNA transcripts may be also related to mtDNA methylation.
There are very few studies that describe the role of DNMTs in the
regulation of the mtDNA methylation, and their results are often
questionable by the lack of clear understanding of the regulation
mechanism. However, the localisation of DNMTs to mitochondria
in different cells has been reported. The mtDNMT1 was defined in
the mitochondria of MEF and human colon carcinoma cells49, the
DNMT3a localises to mitochondria in mouse brain and spinal
cord50 and to mitochondria in muscle tissue of human51. Our
results also show that in MEF cells there is the closest correlation
between changes of the mtDNA content and expression of
mtDnmt1 mRNA transcripts.
The novelty of our study is the analysis of the oregonin effect
on the expression of the mRNA transcripts of mitochondrial iso-
meric form of DNA methyltransferase1-mtDnmt1. Both oregonin
concentrations up-regulated the level of the mtDnmt1 transcripts
in MEFs. In NIH/3T3 cells, the increased level of mitochondrial iso-
form mRNA was provoked only by 100lM of oregonin. Recently
accumulated data21,52 reveal that external factors can alter mtDNA
methylation followed by changing the mitochondrial genes
expression. This process is mediated by mtDnmt1. In accordance
with data of Shock et al.49, hyper expression of mtDnmt1 in mouse
fibroblasts related to the alteration in the expression of Nd1 and
Nd6 genes, coding in mitochondria. Additionally, authors under-
lined that mtDnmt1 is sensitive to regulation by activators that
respond to oxidative stress. The well-known anti-oxidative proper-
ties of oregonin1,10 may further explain the overexpression of the
mtDnmt1 transcripts, as observed in our work.
Here, we showed that polyphenol oregonin affected the
expression of DNMTs transcripts in both NIH/3T3 cells and MEFs
but in some different ways. Its effect is depended on concentra-
tion and specific of cells genotype. The drastic increase of the
DNA methyltransferase mRNA expression (FC between 4.9 and 9.5)
in both types of cells treated with 100 lM of oregonin allows pro-
posing that the molecule exerts some epigenetic toxicity. The
increased level of DNMTs could lead to DNA hypermethylation,
which occurrence at promoter CpG islands is a major epigenetic
mechanism in silencing the genes expression53,54. That could have
both side effects in dependence of silenced genes. The silence of
the viable important genes could disturb the cells and provoke
the diseases development. However, suppression of “negative”
genes could have therapeutic effects.
The main data13,56,57 about the influence of polyphenols,
including curcumin, on the DNA methylation stressed a hypome-
thylation effect due to downregulation of the Dnmt1 mRNA tran-
scripts, which directly correlated with decrease of the DNMT1
protein expression. Here, we observed similar effects for Dnmt1
mRNA in two different cell lines treated with oregonin at 50lM. In
silico study12 of the interaction between curcumin and DNMT1
suggested that curcumin covalently blocks the catalytic thiolate of
DNMT1 to exert its inhibitory effect on DNA methylation. In line
with Zheng et al.55 results, reported the suppression of DNA meth-
yltransferase 3 b by curcumin, we also defined the decrease of
Dnmt3b mRNA transcripts (FC¼ 0.5, p< .05) in NH/3T3 cells
treated with 50 lM of oregonin. In analogy to Liu et al.12, here we
used molecular modeling to predict the possible binding of orego-
nin to DNMT1. Although oregonin does not possess chemically
reactive groups as curcumin, docking results clearly showed that
the two compounds might bind within the catalytic site of DNMT1
in a similar conformation, and partially overlapping with the bind-
ing of the cofactor SAH/SAM. Based on the chemical similarity
between curcumin and oregonin, here we pinpointed the pharma-
cophores that may be relevant for binding to DNMT1 and inhibit-
ing its catalytic function to provide hypomethylation effects.
5. Conclusion
The new properties of the purified oregonin, extracted from the
bark of A. incana, were confirmed in this study. The oregonin
altered the epigenetic marks related to the DNA methylation,
especially, expression of DNMTs mRNAs and mtDNA content in
MEFs in dependence on used concentration and cell genotype.
Molecular docking predicted the ability of oregonin to bind within
the catalytic active site of DNMT1, which suggest that the com-
pound may inhibit DNMT1 enzymatic activity.
However, the development of oregonin as a substance with
potential to regulate the epigenetic changes, needs further investi-
gations, particularly to elucidate the pathways of other epigenetic
mechanisms (histone acetylation, chromatin remodelling) and
genes involved in these processes. Additionally, research is needed
to determine the appropriate dose for treatment without cyto-
toxic effect.
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